DICE Therapeutics
potential to be the best in class oral agent in psoriasis dice exhibited a favorable safety and gazing viable or bid dosing proof of concept to validate and demonstrated clear benefit with improvement in pasi scores | DICE Therapeutics
Company
Deck Type
Deck date
October 2022
Slide
33 of 39
Similar slides by DICE Therapeutics
See diffirences between slides (animation)
Results
October 2022
potential to be the best in class oral agent in psoriasis dice exhibited a favorable safety and gazing viable or bid dosing proof of concept to validate and demonstrated clear benefit with improvement in pasi scores | DICE Therapeutics
Related slides by other companies
AstraZeneca
Investor Day
September 2022
oral factor portfolio | AstraZeneca
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy has exhibited the half life of in | Aeglea BioTherapeutics
Kymera
Investor Presentation
December 2023
oral agent with potential to achieve broad well tolerated anti inflammatory effect in multiple diseases | Kymera
Kymera
Investor Presentation
November 2023
oral agent with potential to achieve broad well tolerated anti inflammatory effect in multiple diseases | Kymera
Other recent decks by DICE Therapeutics
See all presentations (4 decks)
Results
March 2023
Investor Presentation
March 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io